AWH Stockholders Approve Reverse Stock Split, a Prerequisite to a U.S. Exchange ListingPRNewsWire · Aug 31, 2026
AWH Reports Second Quarter 2026 Financial ResultsPRNewsWire · Aug 12, 2026
AWH Reminds Stockholders to Vote on Reverse Stock Split for August 28 Special MeetingPRNewsWire · Aug 10, 2026
AWH to Hold Second Quarter 2026 Earnings Conference Call on Wednesday, August 12, 2026PRNewsWire · Jul 28, 2026Aspira Women's Health Inc., alongside its subsidiaries, specializes in the development and commercialization of diagnostic tools for gynecologic diseases across the United States. Their product portfolio includes tests such as OVA1, OVERA, and OVA1plus, designed to evaluate the risk of ovarian malignancy in women presenting with adnexal masses. Additionally, they provide ASPiRA GenetiX, a genetic screening option for assessing individual susceptibility to gynecologic cancers.